Category C—No structural malformations attributable to risperidone have been reported, the number of exposures is too low to fully assess embryo-fetal risk. There is a risk of EPS and/or withdrawal sx in the newborn if used in the 3rd trimester. Nevertheless, risperidone is indicated for severe debilitating mental disease and the benefits to the mother appear to outweigh the potential embryo-fetal risks.
RID 2.8-9.1%; Limited Human Data—Potential Toxicity
Start at 0.5 mg qhs and ↑ slowly/cautiously. All atypicals may increase mortality in elderly patients by 1.7 times greater than placebo
Start at 0.5 mg qhs and ↑ slowly/cautiously
Start at 0.5 mg qhs and ↑ slowly/cautiously
Developed & Designed by Kevin M. Nasky, D.O. • Built with Bootstrap, PHP & MySQL • Hosted by SiteGround
Last updated February 07 2019 16:52:18. Disclaimer: This website does not provide medical advice, nor is it a substitute for clinical judgment.